Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3

Abstract

This updated Good Publication Practice (GPP) guideline, known as GPP3, builds on earlier versions and provides recommendations for individuals and organizations that contribute to the publication of research results sponsored or supported by pharmaceutical, medical device, diagnostics, and biotechnology companies. The recommendations are designed to help individuals and organizations maintain ethical and transparent publication practices and comply with legal and regulatory requirements. These recommendations cover publications in peer-reviewed journals and presentations (oral or poster) at scientific congresses. The International Society for Medical Publication Professionals invited more than 3000 professionals worldwide to apply for a position on the steering committee, or as a reviewer, for this guideline. The GPP2 authors reviewed all applications (n = 241) and assembled an 18-member steering committee that represented 7 countries and a diversity of publication professions and institutions. From the 174 selected reviewers, 94 sent comments on the second draft, which steering committee members incorporated after discussion and consensus. The resulting guideline includes new sections (Principles of Good Publication Practice for Company-Sponsored Medical Research, Data Sharing, Studies That Should Be Published, and Plagiarism), expands guidance on the International Committee of Medical Journal Editors' authorship criteria and common authorship issues, improves clarity on appropriate author payment and reimbursement, and expands information on the role of medical writers. By following good publication practices (including GPP3), individuals and organizations will show integrity; accountability; and responsibility for accurate, complete, and transparent reporting in their publications and presentations.

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

“…The tolerable all-oral IRd regimen may therefore represent an important treatment option for patients with RRMM, regardless of cytogenetics, but notably for patients with high-risk abnormalities requiring prolonged active therapy to control their aggressive disease. 40 This work was supported by grants from Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Conflict-of-interest disclosure: A. Palumbo has received research funding from Amgen, Novartis, Bristol-Myers Squibb (BMS), Genmab A/S, Celgene, Janssen-Cilag, Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Sanofi Aventis, Merck, and Binding Site, and received personal fees from Amgen, Novartis, BMS, Genmab A/S, Celgene, Janssen-Cilag, Millennium Pharmaceuticals, Inc, Sanofi Aventis, and Merck.…”

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis

“…Writing support during the development of this manuscript was provided by Fiona Scott, a medical writer with FireKite, an Ashfield company, part of UDG Healthcare plc, which was funded by Millennium Pharmaceuticals, Inc., and complied with Good Publication Practice 3 ethical guidelines (Battisti et al , 2015, Ann Int Med , 163, 461‐464).…”

Global reach: Promoting ethical best practices and the quality and integrity of medical publications worldwide

“…2 These updated guidelines expand on earlier versions, include new content on topics such as data sharing and authorship, and provide ten key ''Principles of Good Publication Practice for Company-Sponsored Medical Research.'' ISMPP is also supporting the translation of GPP3 into Chinese and Japanese, further evidence of our commitment to a more global presence.…”